• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比马前列素缓释前房内植入物可降低犬的巩膜静脉压。

Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.

作者信息

Lee Susan S, Burke James, Shen Jie, Almazan Alexandra, Orilla Werhner, Hughes Patrick, Zhang Jane, Li Huajiang, Struble Craig, Miller Paul E, Robinson Michael R

机构信息

Allergan plc, Irvine, CA, USA.

Covance Laboratories Inc., Madison, WI, USA.

出版信息

Vet Ophthalmol. 2018 Jul;21(4):376-381. doi: 10.1111/vop.12522. Epub 2018 Feb 19.

DOI:10.1111/vop.12522
PMID:29457333
Abstract

OBJECTIVE

To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral venous pressure (EVP) in normal dogs.

METHODS

Normotensive beagle dogs were randomized to receive Bimatoprost SR 30 μg (n = 7) or sham injection (needle insertion only, n = 7) in one eye on day 1. EVP was measured with an episcleral venomanometer through day 65. Episcleral aqueous outflow vessels were identified using fluorescence imaging following intracameral injection of indocyanine green in one additional animal. A separate cohort of dogs that had been trained for conscious intraocular pressure (IOP) measurements received Bimatoprost SR 30 μg (n = 8) in one eye; IOP was evaluated through day 66.

RESULTS

Baseline mean EVP was 10.0 mmHg in the Bimatoprost SR group and 10.4 mmHg in the sham group. Eyes treated with Bimatoprost SR exhibited a transient increase in mean EVP that peaked at day 8, followed by a decrease to levels below baseline. From day 29 to day 65, the change in mean EVP from baseline ranged from -2.4 to -3.9 mmHg (P < 0.05 vs. sham). Baseline mean IOP in eyes treated with Bimatoprost SR was 14.9 mmHg, and a steady IOP reduction was maintained through day 66. Bimatoprost SR-treated eyes exhibited a selective, sustained dilation of aqueous outflow vessels that was not observed in sham-treated eyes.

CONCLUSIONS

In normal dogs, Bimatoprost SR was associated with a transient increase in EVP followed by a sustained decrease. Changes in EVP were accompanied by a sustained dilation of aqueous outflow vessels.

摘要

目的

确定比马前列素缓释前房内植入物(比马前列素SR)对正常犬巩膜静脉压(EVP)的影响。

方法

血压正常的比格犬在第1天被随机分为单眼接受30μg比马前列素SR(n = 7)或假注射(仅针头插入,n = 7)。通过第65天使用巩膜静脉压力计测量EVP。在另外一只动物前房内注射吲哚菁绿后,使用荧光成像识别巩膜房水流出血管。另一组经过清醒眼压(IOP)测量训练的犬单眼接受30μg比马前列素SR(n = 8);通过第66天评估IOP。

结果

比马前列素SR组的基线平均EVP为10.0 mmHg,假手术组为10.4 mmHg。接受比马前列素SR治疗的眼睛平均EVP出现短暂升高,在第8天达到峰值,随后降至基线以下水平。从第29天到第65天,平均EVP相对于基线的变化范围为-2.4至-3.9 mmHg(与假手术组相比,P < 0.05)。接受比马前列素SR治疗的眼睛基线平均IOP为14.9 mmHg,并且在第66天之前IOP持续稳定降低。接受比马前列素SR治疗的眼睛表现出房水流出血管的选择性、持续性扩张,而在假手术组中未观察到。

结论

在正常犬中,比马前列素SR与EVP短暂升高随后持续降低有关。EVP的变化伴随着房水流出血管的持续性扩张。

相似文献

1
Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.比马前列素缓释前房内植入物可降低犬的巩膜静脉压。
Vet Ophthalmol. 2018 Jul;21(4):376-381. doi: 10.1111/vop.12522. Epub 2018 Feb 19.
2
Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs.巩膜静脉压与局部和前房内前列腺素类似物的降眼压作用。
J Glaucoma. 2019 Sep;28(9):846-857. doi: 10.1097/IJG.0000000000001307.
3
Dose-Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure.眼内压降低的眼内注射贝美前列素持续释放植入物和局部应用贝美前列素的剂量反应。
J Ocul Pharmacol Ther. 2019 Apr;35(3):138-144. doi: 10.1089/jop.2018.0095. Epub 2019 Jan 30.
4
Topical verapamil and episcleral venous pressure.局部用维拉帕米与巩膜静脉压
Ophthalmology. 1998 Dec;105(12):2251-5. doi: 10.1016/S0161-6420(98)91224-6.
5
Topical application of 0.005% latanoprost increases episcleral venous pressure in normal dogs.0.005%拉坦前列素局部应用可增加正常犬的巩膜静脉压。
Vet Ophthalmol. 2012 Mar;15 Suppl 1:71-8. doi: 10.1111/j.1463-5224.2011.00970.x. Epub 2011 Nov 30.
6
24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.玻璃酸钠治疗干眼症的临床疗效观察
Drugs. 2020 Feb;80(2):167-179. doi: 10.1007/s40265-019-01248-0.
7
Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.眼内持续释放贝美前列素植入物将贝美前列素递送至靶组织,同时减少药物对非靶组织的暴露。
J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):50-57. doi: 10.1089/jop.2018.0067. Epub 2018 Oct 18.
8
Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits.AR-13324对荷兰带兔巩膜静脉压的影响。
J Ocul Pharmacol Ther. 2015 Apr;31(3):146-51. doi: 10.1089/jop.2014.0146. Epub 2015 Mar 10.
9
Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty.选择性激光小梁成形术预处理犬眼的缓释比马前列素植入物的降眼压疗效。
J Ocul Pharmacol Ther. 2022 May;38(4):311-318. doi: 10.1089/jop.2021.0104. Epub 2022 Apr 18.
10
Episcleral venous pressure of mouse eye and effect of body position.小鼠眼球的巩膜静脉压及体位的影响。
Curr Eye Res. 2003 Dec;27(6):355-62. doi: 10.1076/ceyr.27.6.355.18194.

引用本文的文献

1
An Update on Novel Drug Delivery Systems for the Management of Glaucoma.用于青光眼治疗的新型药物递送系统的最新进展
Pharmaceutics. 2025 Aug 21;17(8):1087. doi: 10.3390/pharmaceutics17081087.
2
Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release Innovation.比马前列素前房内植入物(Durysta®):通过缓释创新开启青光眼治疗新时代。
Drug Des Devel Ther. 2025 Jan 31;19:703-714. doi: 10.2147/DDDT.S506520. eCollection 2025.
3
Stem Cell-Based Therapies for Glaucoma Treatment: A Review Bridging the Gap in Veterinary Patients.
基于干细胞的青光眼治疗方法:一篇弥合兽医患者差距的综述
Int J Mol Sci. 2024 Dec 30;26(1):232. doi: 10.3390/ijms26010232.
4
From Eye Care to Hair Growth: Bimatoprost.从眼部护理到头发生长:比马前列素。
Pharmaceuticals (Basel). 2024 Apr 27;17(5):561. doi: 10.3390/ph17050561.
5
Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation.在伴有凝胶支架植入的兔滤过性手术模型中使用新型结膜下持续释放丝裂霉素 C 制剂。
J Ocul Pharmacol Ther. 2024 Jun;40(5):297-308. doi: 10.1089/jop.2023.0100. Epub 2024 May 2.
6
Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients.近期获批的用于降低和控制眼压以减少高眼压症和青光眼患者视力丧失的药物。
Pharmaceuticals (Basel). 2023 May 26;16(6):791. doi: 10.3390/ph16060791.
7
Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress.用于治疗青光眼的眼内纳微尺度药物输送系统:设计策略和最新进展。
J Nanobiotechnology. 2023 Mar 10;21(1):84. doi: 10.1186/s12951-023-01838-x.
8
Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats.基于前列腺素的 rAAV 介导的布朗挪威大鼠青光眼基因治疗。
Commun Biol. 2022 Nov 3;5(1):1169. doi: 10.1038/s42003-022-04134-w.
9
Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma.筛板重塑:青光眼的潜在治疗方法及机制。
Int J Mol Sci. 2022 Jul 22;23(15):8068. doi: 10.3390/ijms23158068.
10
Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty.选择性激光小梁成形术预处理犬眼的缓释比马前列素植入物的降眼压疗效。
J Ocul Pharmacol Ther. 2022 May;38(4):311-318. doi: 10.1089/jop.2021.0104. Epub 2022 Apr 18.